Safety demonstrated across 10 clinical trials, including a 2-year CVOT

No dosage adjustments required in the following special populations1

Gl events2,17,30

Hypoglycaemia1,2,10,17-20,28-30

Pancreatitis2,5,10,17-20,29,30

Diabetic retinopathy complications1

  • Patients with mild, moderate or severe renal impairment

  • Patients with hepatic impairment

  • Patients ≥65 years
  • Gl tolerability comparable with other GLP-1 RAs
  • Low incidence of severe hypoglycaemia* (<3%) across 10 clinical studies
  • No difference in adverse events related to pancreatitis
  • Caution should be exercised when using Ozempic® in patients with
    diabetic retinopathy treated with insulin

— These patients should be monitored and treated according to
clinical guidelines

CVOT=cardiovascular outcomes trial; GI=gastrointestinal; GLP-1 RA=glucagon-like peptide-1 receptor agonist.
*Hypoglycaemia defined as severe (requiring the assistance of another person)

or symptomatic in combination with a blood glucose <3.1 mmol/L.1

GI EVENTS

GI EVENTS

DIABETIC RETINOPATHY COMPLICATIONS

DIABETIC RETINOPATHY COMPLICATIONS

x

GI events

Percentage of patients reporting GI adverse events (AEs) in the head-to-head trials2,17

SUSTAIN 7 vs Trulicity®

Trulicity®
0.75 mg
(n=299)

Ozempic®
0.5 mg
(n=301)

Trulicity®
1.5 mg
(n=299)

Ozempic®
1 mg
(n=300)

Nausea

13

23

20

21

Diarrhoea

8

14

18

14

Vomiting

4

10

10

10

Discontinuation rates due to Gl AEs

2

5

5

6

In general, these reactions were mild or moderate in severity and of short duration.1

GI=gastrointestinal.

x

More information on diabetic retinopathy complications1,21

SUSTAIN 6—CVOT data

Considerations

  • •Diabetic retinopathy complications observed with
     Ozempic® (3.0%) and placebo (1.8%)
  • •>80% of patients with an event had a history of
     retinopathy at baseline
  • •In patients who did not have a history of retinopathy,
     the number of events was similar for Ozempic®
     and placebo
  • •Rapid improvement in glucose control has been associated with a
     temporary worsening of diabetic retinopathy
  • •Long-term glycaemic control decreases the risk of diabetic retinopathy
  • •Caution should be exercised when using Ozempic® in patients
     with diabetic retinopathy treated with insulin

— These patients should be monitored and treated according to
    clinical guidelines

For additional information about SUSTAIN 6, please see the study design.

CVOT=cardiovascular outcomes trial.